Proteome Sciences PLC Grant of Options and PDMR/director shareholdings (3290I)
01 Décembre 2022 - 5:38PM
UK Regulatory
TIDMPRM
RNS Number : 3290I
Proteome Sciences PLC
01 December 2022
1 December 2022
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Grant of Options and PDMR/director shareholdings
Proteome Sciences announces that further to the announcement of
Abdelghani Omari's appointment as Chief Financial Officer on 18
August 2022 (the "Appointment Announcement"), Mr Omari has today
been granted 4,000,000 options by the Company under the Company's
share option scheme ("Options"). The Options are to be issued at
nominal value and will vest in three equal annual tranches on 1
September 2023, 1 September 2024 and 1 September 2025. Each Option
is exercisable into one Ordinary Share and once vested, can be
exercised up until the 10th anniversary.
The Company notes that in the earlier Appointment Announcement,
it said the Options are exercisable at the closing price of the
Company's ordinary shares ("Ordinary Shares") on the date the
Options are granted. The Company acknowledges that this statement
was incorrect.
The Options granted to Mr Omari represent approximately 1.36 per
cent of the Company's current issued share capital. In total
24,471,000 Options are now outstanding, representing approximately
8.30 per cent of the Company's current issued share capital.
Further details and the information required in accordance with
the requirements of Article 19(3) of the Market Abuse Regulation No
596/2014 (as retained and applicable in the UK pursuant to section
3 of the European Union (Withdrawal) Act 2018) ("UK MAR") are set
out at the end of this announcement.
For further information:
Proteome Sciences plc
Proteome Sciences plc
Dr Mariola Soehngen, Chief Executive Tel: +44 (0)20 7043 2116
Officer
Dr Ian Pike, Chief Scientific Officer
Richard Dennis, Chief Commercial Officer
Allenby Capital Limited (AIM Nominated Adviser & Broker)
John Depasquale / Jeremy Porter (Corporate Tel: +44 (0) 20 3328 5656
Finance)
Tony Quirke (Sales)
About Proteome Sciences plc. ( www.proteomics.com )
Proteome Sciences plc is a specialist provider of contract
proteomics services to enable drug discovery, development and
biomarker identification, and employs proprietary workflows for the
optimum analysis of tissues, cells and body fluids. SysQuant(R) and
TMT(R) MS2 are unbiased methods for identifying and contextualising
new targets and defining mechanisms of biological activity, while
analysis using Super-Depletion and TMTcalibrator(TM) provides
access to over 8,500 circulating plasma proteins for the discovery
of disease-related biomarkers. Targeted assay development using
mass spectrometry delivers high sensitivity, interference-free
biomarker analyses in situations where standard ELISA assays are
not available.
The Company has its headquarters in Cobham, UK, with laboratory
facilities in Frankfurt, Germany.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
The below notification is made in accordance with the
requirements of UK MAR.
1. Details of the person discharging managerial responsibilities/person
closely associated
a) Name: Abdelghani Omari
----------------------------------------- ----------------------------------
Reason for the notification
2.
-----------------------------------------------------------------------------
a) Position/status: Chief Financial Officer
----------------------------------------- ----------------------------------
b) Initial notification/Amendment: Initial Notification
----------------------------------------- ----------------------------------
Details of the issuer, emission allowance market participant,
3. auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------
a) Name: Proteome Sciences Plc
----------------------------------------- ----------------------------------
b) LEI: 213800Q62ICXANKU2986
----------------------------------------- ----------------------------------
Details of the transaction(s): section to be repeated for
4. (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------------
a) Description of the financial instrument, Ordinary Shares of 1p
type of instrument: nominal value
Identification code: GB0003104196
----------------------------------------- ----------------------------------
b) Nature of the transaction: Grant of options under
the Proteome Sciences
plc 2021 Long Term Share
Incentive Plan to acquire
ordinary shares of 1p
each in Proteome Sciences
plc
----------------------------------------- ----------------------------------
c) Price(s) and volume(s): Price(s) Volume(s)
GBP0.01 4,000,000
----------
----------------------------------------- ----------------------------------
d) Aggregated information: Single transaction as
* Aggregated volume: in c) above Average Volume(s)
Price
GBP0.01 4,000,000
* Price: ----------
----------------------------------------- ----------------------------------
e) Date of the transaction: 1 December 2022
----------------------------------------- ----------------------------------
f) Place of the transaction: N/A
----------------------------------------- ----------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHQFLFBLLLXFBQ
(END) Dow Jones Newswires
December 01, 2022 11:38 ET (16:38 GMT)
Proteome Sciences (AQSE:PRM.GB)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Proteome Sciences (AQSE:PRM.GB)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
